Tasly Pharmaceutical Group (600535) Stock Overview
Engages in the pharmaceutical business in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
600535 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Tasly Pharmaceutical Group Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥15.80 |
| 52 Week High | CN¥17.77 |
| 52 Week Low | CN¥13.51 |
| Beta | 0.34 |
| 1 Month Change | -3.66% |
| 3 Month Change | -0.75% |
| 1 Year Change | -2.17% |
| 3 Year Change | 61.89% |
| 5 Year Change | -8.14% |
| Change since IPO | 370.43% |
Recent News & Updates
Recent updates
An Intrinsic Calculation For Tasly Pharmaceutical Group Co., Ltd (SHSE:600535) Suggests It's 23% Undervalued
Mar 25
There May Be Some Bright Spots In Tasly Pharmaceutical Group's (SHSE:600535) Earnings
Mar 03Earnings Miss: Tasly Pharmaceutical Group Co., Ltd Missed EPS By 7.6% And Analysts Are Revising Their Forecasts
Feb 26Investors Continue Waiting On Sidelines For Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)
Nov 17Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?
Jul 22Estimating The Intrinsic Value Of Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)
Jun 13The Market Doesn't Like What It Sees From Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Earnings Yet
May 13Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively
Apr 26Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?
Mar 15Shareholder Returns
| 600535 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 0.6% | 0.7% | 1.8% |
| 1Y | -2.2% | 17.6% | 24.1% |
Return vs Industry: 600535 underperformed the CN Pharmaceuticals industry which returned 17.6% over the past year.
Return vs Market: 600535 underperformed the CN Market which returned 24.1% over the past year.
Price Volatility
| 600535 volatility | |
|---|---|
| 600535 Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 600535 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600535's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 10,958 | Jin Yong Cai | www.taslypharma.com |
Tasly Pharmaceutical Group Co., Ltd engages in the pharmaceutical business in China and internationally. The company provides prescription drugs covering various therapeutic areas, including cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, soothe the nerves, pruritus, and andrological areas, as well as over-the-counter drugs. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is headquartered in Tianjin, China.
Tasly Pharmaceutical Group Co., Ltd Fundamentals Summary
| 600535 fundamental statistics | |
|---|---|
| Market cap | CN¥23.60b |
| Earnings (TTM) | CN¥1.07b |
| Revenue (TTM) | CN¥8.41b |
Is 600535 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600535 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.41b |
| Cost of Revenue | CN¥2.79b |
| Gross Profit | CN¥5.63b |
| Other Expenses | CN¥4.56b |
| Earnings | CN¥1.07b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 25, 2025
| Earnings per share (EPS) | 0.71 |
| Gross Margin | 66.88% |
| Net Profit Margin | 12.69% |
| Debt/Equity Ratio | 12.7% |
How did 600535 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 02:36 |
| End of Day Share Price | 2025/09/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tasly Pharmaceutical Group Co., Ltd is covered by 34 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Changming He | BOCI Research Ltd. |
| Jun Liu | Changjiang Securities Co. LTD. |
| Fusheng Cheung | China Galaxy International Securities (Hong Kong) |